Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
: c# R; i5 z) B f0 n! j! J. h V
, G6 H- q# B9 h3 |1 l* g" m3 F. n) K& F- I$ j2 P, c
Sub-category:
6 c1 q% O" M2 ^1 A3 G6 t6 nMolecular Targets ( J, |+ I1 _* j1 |6 _1 R5 Z' x
6 _2 b% o2 i( j/ \
5 x8 m; b% c6 [7 ~& Q* n+ aCategory:$ l2 W& @2 P, C7 M
Tumor Biology
' t8 s7 d7 D$ G5 ^
# i% B/ ~2 H! N& K9 p4 r( I5 @! n* D7 }0 }- i% r# ^7 l3 p& p( r
Meeting:7 \1 D2 z4 h7 `; L
2011 ASCO Annual Meeting 2 x. x, Q. I& _) H
8 i, O0 P8 u& {9 G: E
) ^0 G) ~0 V6 t8 Q3 }6 X: _Session Type and Session Title:' ~1 Q& f: {* F- I( {3 K* R
Poster Discussion Session, Tumor Biology
% |2 y. L* r A' U! X" U% R8 b1 `
- l7 j P4 e3 k( @. lAbstract No:
7 N9 N# o- Z" @10517 " L: Y! K( @( K+ k$ l$ r
& q8 {" F! L& z/ Z" g5 L) N( B
/ h( B S" ?* R! l+ L* @Citation:3 ]1 v/ r# H( {3 |$ _7 ` J* q
J Clin Oncol 29: 2011 (suppl; abstr 10517)
. r8 r6 b4 I) B; N, f) d+ Y! ~& Q+ u% q
5 c/ \& O2 S9 @" Z& G
Author(s):2 h! ^% j- u9 N
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 5 m( G1 g4 `! a! y
( N. a( ^1 F! n) e1 a+ F' }) _1 e
! n1 f9 x U/ f1 s6 C6 j& N; x7 S G% D( L' M3 i( C1 ?
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.& ?8 J" N1 I& x5 t) r# p" A
8 y3 m1 M1 G# C
Abstract Disclosures1 T' l* g- z" P8 z
# K8 M( ~. H: u! r1 n
Abstract:' u2 \- _8 F+ K0 r1 U# v; o
3 z, U! h, |2 C! [
0 p6 P* s0 d7 S6 T& w* _. oBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.% C0 X' O1 F. _/ ^; e
f1 `) x2 ]3 Z$ T9 D3 E
2 A# J# j8 r9 k5 S, y6 h |
显身卡
